A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4810-4819

  Tworoger, Shelley S ^a,b   Eliassen, A Heather ^a,b   Zhang, Xuehong ^a,b   Qian, Jing ^b   Sluss, Patrick M ^b   Rosner, Bernard A ^a,c   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROLACTIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; PROLACTIN; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881433826     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0665     Document Type: Article

References (38)

1. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
2. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25: 1482-8.
3. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003; 14:599-607.
4. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-21.
5. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9:575-9.
6. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
7. Berinder K, Akre O, Granath F, Hulting A-L. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011;165:209-15.
8. Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010;206:1-11.
9. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302.
10. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and subsequent risk of breast cancer over 20 years of follow-up. Breast Cancer Res Treat 2013;137:883-92.
11. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006;66:2476-82.
12. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 1989;35:2313-6.
13. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004;64:6814-9.
14. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-54.
15. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972-8.
16. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
17. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 2008;167:653-66.
18. Rosner BA. Fundamentals of Biostatistics. 6th ed. Belmont, CA: Duxbury Press; 2005.
19. Eliassen AH, Tworoger SS, Hankinson SE. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 2007; 120:1536-41.
20. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-5.
21. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000;26:540-7.
22. Lachelin GC, Yen SC, Alksne JF. Hormonal changes following hypophysectomy in humans. Obstet Gynecol 1977;50:333-9.
23. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett 2006;243:160-9.
24. Jacobson EM, Hugo ER, Borcherding DC, Ben-Jonathan N. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov Med 2011;11:315-24.
25. Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, Thüsen von der JH, Twickler MTB, et al. Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med 2012;16:2035-48.
26. Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal 2011;23:1794-805.
27. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999;140:5447-50.
28. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A 1999;96:1246-51.
29. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003;79:241-52.
30. Rasmussen LM, Frederiksen KS, Din N, Galsgaard E, Christensen L, Berchtold MW, et al. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer 2010;17:809-22.
31. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 2004;88:69-77.
32. Tworoger SS, Rosner BA, Willett WC, Hankinson SE. The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2011;13:R99.
33. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 2011;13:R11.
34. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalphanegative mammary cancer in transgenic mice. Oncogene 2003;22: 4664-74.
35. Gonzalez L, Zambrano A, Lazaro-Trueba I, Lopez E, Gonzalez JJA, Martín-Perez J, et al. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 2009;28:1298-308.
36. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354-69.
37. Hoffmann T, Penel C, Ronin C. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 1993;16:807-16.
38. Yen SC, Barbieri RL. Reproductive endocrinology: physiology, pathophysiology, and clinical management. 4th ed. Philadelphia, PA: W.B. Saunders; 1999.